leukotriene biosynthesis

L 651896 is a novel leukotriene biosynthesis and 5-lipoxygenase inhibitor for the study of respiratory and cardiovascular diseases.

CJ-13,610 is an orally active and nonredox-type inhibitor of 5-lipoxygenase (5-LOX). CJ-13,610 inhibits the biosynthesis of leukotriene B4 and regulates the expression of IL-6 mRNA in macrophages.

BIRM 271 is a novel arachidonic acid release inhibitor that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils. BIRM 271 and BIRM 270 are enantiomers that inhibit the production of leukotriene B4 with IC50 of 40 nM.

MK-886 (L 663536) is an inhibitor of leukotriene biosynthesis, acting by inhibiting the 5-lipoxygenase-activating protein (FLAP), and serves as a moderately potent PPARα antagonist.

HFI-142 is a small-molecule inhibitor that binds specifically to the active site of aminopeptidase N and suppresses its enzymatic activity. HFI-142 has been demonstrated to inhibit leukotriene A4 biosynthesis in red blood cells, an effect that may offer therapeutic potential for the research in cancer by modulating inflammatory and metabolic pathways implicated in tumor growth and progression. HFI-142 was also shown to inhibit the activity of additional aminopeptidases, including aminopeptidase N, as well as other enzymes associated with protein metabolism.

Quiflapon (MK-591) causes cell apoptosis. Quiflapon is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor (IC50: 1.6 nM in a FLAP binding assay) and is also an effective and orally active Leukotriene biosynthesis (LT) inhibitor (IC50: 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively).

L 669083 is two classes of potent leukotriene biosynthesis inhibitors photoaffinity analogue.

L 674573 is an inhibitor of leukotriene biosynthesis.

L 689037 is an inhibitor of leukotriene biosynthesis.

L 691678 is a potent leukotriene biosynthesis inhibitor.

DG-051 is a novel leukotriene A4 (LTA4H) hydrolase inhibitor of leukotriene B4 biosynthesis.

Baicalein monohydrate is an inhibitor of 12-lipoxygenase, leukotriene biosynthesis and release of lysosomal enzymes. It also inhibits cellular Ca2+ uptake and mobilization and adjuvant-induced arthritis.

MK-886 sodium salt inhibits leukotriene biosynthesis in leukocytes.

20-Carboxy-Leukotriene B4 (20-COOH LTB4), a metabolite of Leukotriene B4 (LTB4), exhibits high affinity for the BLT1 receptor and significantly inhibits LTB4-mediated neutrophil responses such as migration, degranulation, and leukotriene biosynthesis [1].

Tryptanthrin is a natural DNA gyrase inhibitor.

Prostaglandin E2 Serinol Amide acts as a weak inhibitor against the hydrolysis of [3H]2-oleoylglycerol, but it is non-hydrolyzable and cannot produce PGE2. Consequently, it is unable to inhibit leukotriene B4 biosynthesis, superoxide production, migration, and the release of antimicrobial peptides [1].

1-Methyl-2-nonylquinolin-4(1H)-one has anti-inflammatory activity, it exhibits inhibitory activity on leukotriene biosynthesis in a bioassay using human polymorphonuclear granulocytes, with IC50 values of 12.1 microM.

Stilbostemin A, stilbostemin B , stilbostemin D , stilbostemin F , and stilbostemin G show structure-dependent inhibition of leukotriene biosynthesis with IC(50) values ranging from 3.7 to >50 microM.

(Z)-1-Methyl-2-(undec-6-enyl)quinolin-4(1H)-one shows strong inhibitory activity on leukotriene biosynthesis in human polymorphonuclear granulocytes, and it is very effective against mycobacteria.

9,11-Dehydro-β-boswellic acid is a compound with urease inhibitory activity and acts as an inhibitor of 5-lipoxygenase (5-LO), a critical enzyme in leukotriene biosynthesis.